Formulary Decisions

Search for the outcome of decisions made by the Formulary Committee

Filter
Select filter(s)
Certolizumab pegol
Cimzia
Routinely available
NICE (TA375 (SMC 590/09))
29/03/2023

Indication

Moderate to severe active rheumatoid arthritis in adult patients.

Moderate to severe active rheumatoid arthritis in adult patients.

Therapeutic Area

Musculoskeletal and joint diseases

Status Description

Routinely available in line with national guidance

Formulation

200mg/mL solution for injection (prefilled syringe)

Comments

March 23 - ERF Status update included in the pathway Treatment of Rheumatoid Arthritis with biologics in pregnancy.

Link to Advice

TA375 (SMC 590/09)

Advice Published

26/01/2016